Market Closed - Xetra 11:44:33 2024-04-25 am EDT After market 12:21:41 pm
9.16 EUR -4.98% Intraday chart for Evotec SE 9.205 +0.49%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
The specter of stagflation rears its ugly head again Our Logo
EVOTEC : Buy rating from Deutsche Bank ZD
Top Midday Decliners MT
Dpa-AFX Overview: COMPANIES from 24.04.2024 - 15:15 DP
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday MT
Transcript : Evotec SE, 2023 Earnings Call, Apr 24, 2024
Technology Stocks Gain Amid Tesla's EV Plans as US Equity Futures Turn Mostly Higher Pre-Bell MT
Sector Update: Health Care MT
Top Premarket Decliners MT
RBC upgrades Evotec to 'Outperform' after figures and outlook DP
EVOTEC : Warburg Research reaffirms its Buy rating ZD
Jefferies rates Evotec a 'Buy' after figures and outlook DP
EVOTEC : Jefferies reaffirms its Buy rating ZD
EVOTEC : RBC keeps its Buy rating ZD
Evotec crashes - Too much uncertainty DP
Evotec SE Reports Earnings Results for the Full Year Ended December 31, 2023 CI
U.S. Futures, European Stocks Mixed DJ
Evotec under pressure - outlook disappointed DP
WDH/Evotec aims to return to profitable growth in 2024 DP
Evotec aims to return to profitable growth in 2024 DP
Evotec SE Provides Earnings Guidance for the Year 2024 CI
Germany's Evotec Appoints Permanent CEO MT
Evotec Taps Christian Wojczewski as New CEO MT
Germany's Evotec appoints Christian Wojczewski as CEO RE
Evotec finds permanent CEO solution: Christian Wojczewski takes over from July 1 DP
Chart Evotec SE
More charts
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.64 EUR
Average target price
25.4 EUR
Spread / Average Target
+163.49%
Consensus
  1. Stock Market
  2. Equities
  3. EVT Stock
  4. News Evotec SE
  5. Evotec Confirms FY21 Earnings Outlook, Midterm Targets